Tumor-on-a-chip method reveals timing as a factor in glioblastoma immunotherapy
Researchers have developed a 'tumor-on-a-chip' microfluidic platform to study how the timing of immune cell interactions affects glioblastoma treatment. The study found that the sequence in which immune cells are introduced to cancer cells significantly alters the effectiveness of immunotherapy.
Why it matters
This discovery provides a new strategy for optimizing personalized cancer treatments, potentially improving outcomes for patients with highly lethal brain tumors.
edited by Sadie Harley , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Graphical abstract. Credit: Neuro-Oncology (2026). DOI: 10.1093/neuonc/noag151 A joint research team led by professors Sungsu Park of Sungkyunkwan University and Sun-Ha Paek of Seoul National University College of Medicine has demonstrated for the first time that the sequence in which immune cells interact with cancer cells can critically influence the therapeutic response in glioblastoma.
The findings, published in the journal Neuro-Oncology , reveal the importance of timing in tumor-immune interactions and suggest a new strategy for optimizing personalized cancer immunotherapy.
Glioblastoma (GBM), one of the most lethal brain tumors, is characterized by a strongly immunosuppressive microenvironment driven in part by the extensive infiltration of microglia, the brain's resident immune cells.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in